Cytek Biosciences, Inc. (CTKB)
CTKB moved a median of -0.12% 30 minutes after news, and +0.44% by the close. How CTKB actually reacts to news — the realized, point-in-time move the market made, measured across 304 labeled events over the last three years with zero look-ahead.
CTKB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 304 |
| 30-min | -0.12% | 46% | 304 |
| 60-min | +0.12% | 52% | 304 |
| to close | +0.44% | 56% | 302 |
| Middle 50% of CTKB reactions | -1.06% to +1.35% |
|---|---|
| Median reaction (30-min) | -0.12% |
| Measured reactions | 304 |
Half of all Cytek Biosciences, Inc. news events land between -1.06% and +1.35% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CTKB reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Rating reiterations | 18 | -0.10% | 44% | -0.94% |
| Price-target cuts | 10 | -1.02% | 10% | -0.82% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how CTKB ranks against every other measured name →
That’s how CTKB usually reacts — get an email when it moves on news →Email me when CTKB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CTKB's baseline. Nothing else.
Recent CTKB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Cytek Biosciences, Inc. For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | +1.04% | +3.47% | |
| Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool | Press release | GlobeNewswire | -0.62% | +1.60% | |
| Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry | Press release | GlobeNewswire | -0.44% | +3.05% | |
| Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS | Press release | GlobeNewswire | +1.25% | +0.64% | |
| Cytek Biosciences to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.54% | +0.64% | |
| Form 8-K Cytek Biosciences, Inc. For: Aug 21 | SEC filing · Form 8-K | SEC EDGAR | -3.96% | -7.50% | |
| Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding | Press release | GlobeNewswire | -3.96% | -7.50% | |
| Cytek Biosciences Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | -4.35% | -4.80% | |
| Form 10-Q Cytek Biosciences, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.35% | -4.80% | |
| Form 8-K Cytek Biosciences, Inc. For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -4.35% | -4.80% | |
| Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026 | Press release | GlobeNewswire | +3.91% | +1.79% | |
| Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement | Press release | GlobeNewswire | +0.32% | -0.64% | |
| Form 8-K Cytek Biosciences, Inc. For: Jul 09 | SEC filing · Form 8-K | SEC EDGAR | +0.32% | -0.64% | |
| Form 8-K Cytek Biosciences, Inc. For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +0.89% | -0.22% | |
| Form 8-K Cytek Biosciences, Inc. For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -1.34% | -2.93% | |
| Cytek Biosciences to participate at the Singular Research’s Las Vegas Invitational Conference | Press release | GlobeNewswire | -1.36% | -0.74% | |
| Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026 | Press release | GlobeNewswire | -0.95% | -3.34% | |
| Form 8-K Cytek Biosciences, Inc. For: May 27 | SEC filing · Form 8-K | SEC EDGAR | -0.95% | -3.34% | |
| Form SD Cytek Biosciences, Inc. | SEC filing · Form SD | SEC EDGAR | -1.66% | -0.71% | |
| Cytek Biosciences Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | +6.68% | +2.67% | |
| Form 10-Q Cytek Biosciences, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +6.68% | +2.67% | |
| Form 8-K Cytek Biosciences, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +6.68% | +2.67% | |
| Form ARS Cytek Biosciences, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.24% | -1.77% | |
| Form DEF 14A Cytek Biosciences, Inc. For: Jun 10 | SEC filing · Form DEF | SEC EDGAR | -0.24% | -1.77% | |
| Form DEFA14A Cytek Biosciences, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.24% | -1.77% | |
| Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026 | Press release | GlobeNewswire | +0.82% | +3.53% | |
| Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact | Press release | GlobeNewswire | -2.06% | -2.98% | |
| Form S-8 Cytek Biosciences, Inc. | SEC filing · Form S-8 | SEC EDGAR | +1.58% | -0.23% | |
| Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook | Press release | GlobeNewswire | +0.09% | +5.16% | |
| Form 10-K Cytek Biosciences, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.09% | +5.16% | |
| Form 8-K Cytek Biosciences, Inc. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | +0.09% | +5.16% | |
| Cytek Biosciences to participate at the TD Cowen 46th Annual Health Care Conference | Press release | GlobeNewswire | -1.19% | +3.33% | |
| Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 | Press release | GlobeNewswire | +0.59% | +0.71% | |
| Form 8-K Cytek Biosciences, Inc. For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | +0.18% | -2.29% | |
| Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results | Press release | GlobeNewswire | +4.42% | +2.65% | |
| TIME Recognizes Cytek® Biosciences as One of America’s Growth Leaders of 2026 | Press release | GlobeNewswire | +0.42% | — | |
| Cytek Biosciences to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.11% | +2.67% | |
| Cytek® Muse® Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year | Press release | GlobeNewswire | +1.11% | +2.67% | |
| Cytek Biosciences Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | +3.04% | +6.32% | |
| Form 10-Q Cytek Biosciences, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.04% | +6.32% | |
| Form 8-K Cytek Biosciences, Inc. For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | +3.04% | +6.32% | |
| Cytek® Biosciences Deepens Commitment to Expanding Access to Flow Cytometry | Press release | GlobeNewswire | -0.75% | -4.50% | |
| Cytek Biosciences to Report Third Quarter 2025 Financial Results on November 5, 2025 | Press release | GlobeNewswire | +0.48% | +0.97% | |
| Cytek® Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth | Press release | GlobeNewswire | -0.24% | -2.66% | |
| Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences ICCS and ESCCA | Press release | GlobeNewswire | +0.67% | +9.84% | |
| Cytek Biosciences to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.00% | +1.96% | |
| Cytek Biosciences Reports Second Quarter 2025 Financial Results | Press release | GlobeNewswire | +1.64% | +5.66% | |
| Form 10-Q Cytek Biosciences, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.64% | +5.66% | |
| Form 8-K Cytek Biosciences, Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +1.64% | +5.66% | |
| Cytek Biosciences to Report Second Quarter 2025 Financial Results on August 6, 2025 | Press release | GlobeNewswire | -1.20% | -0.30% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CTKB section they belong to.
Where else CTKB is measured.
CTKB earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Cytek Biosciences, Inc.'s median reaction calculated?
Every labeled CTKB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 304 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of CTKB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CTKB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.